Sign Up to like & get
recommendations!
0
Published in 2018 at "European Journal of Pharmaceutical Sciences"
DOI: 10.1016/j.ejps.2018.07.005
Abstract: &NA; Benznidazole (BZ), first‐line drug for Chagas treatment, is available as immediate‐release tablets. High frequency of administration, long‐term therapy, and side effects of BZ conspire against treatment adherence, and negatively impact in therapeutic success. We…
read more here.
Keywords:
treatment;
preclinical pharmacokinetics;
loaded interpolyelectrolyte;
benznidazole ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Pharmacological research"
DOI: 10.1016/j.phrs.2020.104907
Abstract: Phenothiazines inhibit major antioxidant defense mechanisms in trypanosomatids and exhibit potent cytotoxic effects in vitro. However, the relevance of these drugs in the treatment of Trypanosoma cruzi-induced acute myocarditis is poorly explored, especially in combination…
read more here.
Keywords:
heart;
cruzi induced;
tdz;
cruzi ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-14986-6
Abstract: Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects 5–8 million people in Latin America. Although the nitroheterocyclic compound benznidazole has been the front-line drug for several decades, treatment failures are common.…
read more here.
Keywords:
genome wide;
drug;
front line;
resistance ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Molecular Microbiology"
DOI: 10.1111/mmi.14763
Abstract: Nitroheterocycles represent an important class of compound used to treat trypanosomiasis. They often function as prodrugs and can undergo type I nitroreductase (NTR1)‐mediated activation before promoting their antiparasitic activities although the nature of these downstream…
read more here.
Keywords:
dna damage;
mechanism;
activation;
damage ... See more keywords